Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: A cost-utility analysis

Canadian Journal of Clinical Pharmacology

Volumn 8, Issue 4, 2001, Pages 199-206

  Oh, Paul I ^a,f   Iskedjian, Michael ^b   Addis, Antonio ^c   Lanctôt, Krista ^a,d,e   Einarson, Thomas R ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Harmideas Research and Consulting Inc   (Canada)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

^e Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^f Division of Clinical Pharmacology   (Canada)

Author keywords

Economic; Schizophrenia; Utility

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL;

ARTICLE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE UTILIZATION; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; SCHIZOPHRENIA; STATISTICAL MODEL;

EID: 0035688899     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. La clozapine dans le traitement de la schizophrenie refractaire: Regles et directives canadiennes
2. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
3. Stability of psychopathology dimensions in chronic schizophrenia: Response to clozapine treatment
4. The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the United Kingdom
5. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis
6. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-medicated responses in schizophrenia: Implications for the mechanism of action of clozapine
7. Does clozapine cause tardive dyskinesia?
8. The effect of clozapine on pre-existing tardive dyskinesia
9. Meta-analysis in clinical trials
10. Pharmacoeconomic application of meta-analysis for single group: Antifungal onychomycosis lacquers as example
11. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance
12. The risks and benefits of clozapine versus chlorpromazine
13. Clinical and biologic response to clozapine in patients with schizophrenia
14. Clozapine efficacy in schizophrenic nonresponders
15. Effects of dozapine on positive and negative symptoms in outpatients with schizophrenia
16. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients
17. A two year clincial and economic follow-up of patients on clozapine
18. Costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom
19. Neuroleptic withdrawal in schizophrenic patients